Diabetes latest guudlines
Reading File
Searching PubMed
"diabetes mellitus"[MeSH Terms] AND "guideline"[pt]
Searching the Web
ADA Standards of Medical Care in Diabetes 2025 2026 guidelines summary
Reading Web Page
ADA 2026 diabetes guidelines key updates recommendations
Reading Article
Finding Sources
Here is a comprehensive summary of the latest diabetes guidelines as of 2026:
Diabetes Latest Guidelines (ADA 2026 + AACE 2026)
ADA Standards of Care in Diabetes - 2026
Published in the January 2026 supplement of Diabetes Care, this is the gold-standard annual update from the American Diabetes Association.
1. Diabetes Technology - Major Updates
Automated Insulin Delivery (AID) is now the preferred insulin delivery method - this is the biggest change for 2026:
- Recommended for all people with type 1 diabetes
- Now recommended for adults with type 2 diabetes on insulin (first time this received the strongest recommendation level)
- AID systems improve time-in-range, reduce hypoglycemia, and lower the daily burden of diabetes management
Continuous Glucose Monitoring (CGM):
- Recommended at diabetes onset and anytime thereafter for adults on insulin therapy
- Also recommended for those on non-insulin therapies that can cause hypoglycemia
- Specifically recommended for older adults with T1D or T2D on insulin to reduce hypoglycemia risk
2. Pharmacological Treatment
Type 2 Diabetes - Comorbidity-driven prescribing remains the core approach:
| Comorbidity | Preferred Agent |
|---|---|
| Heart failure (HFpEF) | Dual GIP/GLP-1 RA (tirzepatide) OR GLP-1 RA with proven HF benefits |
| Established CVD / high CV risk | GLP-1 RA or SGLT-2 inhibitor |
| Chronic kidney disease (CKD) | SGLT-2 inhibitor; GLP-1-based therapy now extended to advanced CKD |
| Obesity | GLP-1 RA / dual GIP-GLP-1 RA (tirzepatide) |
New recommendation (9.9a): Dual GIP/GLP-1 RA (tirzepatide) is specifically recommended for T2D with heart failure with preserved ejection fraction (HFpEF) due to demonstrated reduction in HF-related symptoms and events.
GLP-1-based therapy extended to advanced CKD - a significant expansion from prior guidelines that had limited use in severe renal impairment.
3. Glycemic Targets
- HbA1c < 7% remains the general target for most non-pregnant adults
- CGM targets: Time-in-range (TIR) >70%, time below range <4%
- Individualized targets based on patient age, comorbidities, hypoglycemia risk, and life expectancy
4. Lifestyle and Behavioral Management
- Physical activity: Now emphasizes ≥60 min/day of moderate-to-vigorous activity, with bone- and muscle-strengthening activities ≥3 times/week
- New guidance added on preventing exercise-related hypoglycemia and hyperglycemia
- Tobacco/e-cigarettes/vaping: Routine assessment and avoidance recommended; combination cessation counseling + pharmacotherapy recommended
- Mental health: Referral to a qualified behavioral health professional now recommended if diabetes distress is not adequately addressed during appointments
5. Nutrition
- No major dietary pattern mandated; Mediterranean, DASH, plant-based, low-carb diets all recognized
- Older adults: At least 0.8 g/kg/day protein now specifically recommended
6. Older Adults
- Blood pressure goal: <130/80 mmHg for most older adults when achievable safely
- More relaxed BP goal (<140/90 mmHg) for those with poor health, limited life expectancy, or high adverse-effect risk
- CGM now explicitly recommended for older adults on insulin
7. Diabetic Neuropathy and Foot Care
- Neuropathy diagnosis updated to incorporate the Ipswich touch test
- Combination therapy emphasized for neuropathic pain relief
- Emerging technologies discussed: smart mats, insoles, socks for self-monitoring foot temperature to detect early pre-ulceration
- Stronger emphasis on prompt infection management in diabetic foot complications
AACE 2026 Algorithm for Type 2 Diabetes Management
Published in Endocrine Practice (PMID: 41842862), the AACE updated its comprehensive algorithm with 11 sections. Key highlights:
- Lifestyle modification + treatment of overweight/obesity identified as primary pillars
- New diabetes classification algorithm - ensures clinicians consider causes beyond T2D (MODY, LADA, secondary diabetes, etc.)
- Complications- and comorbidities-centric approach for pharmacological choices, not just glucose levels
- Guidance on dyslipidemia and hypertension management in T2D
- Updated vaccine recommendations for adults with T2D
DCRM 2.0 - Multispecialty Cardiorenal-Metabolic Guidelines (2024)
A multispecialty consensus (PMID: 38852020) integrating diabetes with cardiovascular and kidney disease management:
- Simultaneous management of diabetes, CKD, and CV risk using SGLT-2i and GLP-1 RA
- Emphasizes organ-protective drug choice over glucose-lowering potency alone
BMJ Living Guideline on T2D Medications (2025)
Published in BMJ (PMID: 40813129), this "living" guideline continuously updates on cardiovascular, kidney, and weight-loss effects of T2D therapeutics - useful for evidence-based drug comparisons in real time.
Bottom Line - Key Themes Across 2026 Guidelines
- AID systems are now preferred over MDI or standard pumps for all insulin users
- GLP-1 RAs and SGLT-2i remain the backbone of T2D treatment beyond glycemia, with expanded CKD indications
- Tirzepatide (dual GIP/GLP-1) has a named recommendation for HFpEF
- Person-centered, shared decision-making underpins all recommendations
- Obesity treatment is now fully integrated into diabetes management, not an afterthought
The full 2026 ADA Standards of Care is available at diabetes.org and as a supplement to Diabetes Care (January 2026).
This is a shared conversation. Sign in to Orris to start your own chat.